Valuation : Zai Lab Limited

Market Cap 2.94B 2.53B 2.38B 2.18B 4.07B 278B 4.09B 28.17B 10.93B 143B 11.06B 10.82B 460B P/E 2026 *
-11.9x
P/E 2027 * -11.8x
Enterprise Value 2.49B 2.14B 2.01B 1.84B 3.44B 235B 3.45B 23.79B 9.23B 120B 9.34B 9.14B 388B EV / Sales 2026 *
5.88x
EV / Sales 2027 * 4.64x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-0.88%
Current month+3.70%
1 month+42.68%
3 months+60.00%
6 months+38.27%
Current year+53.42%
1 week 21.2
Extreme 21.2
22.4
1 month 18.1
Extreme 18.1
22.8
Current year 13.2
Extreme 13.2
22.8
1 year 13.2
Extreme 13.2
29.4
3 years 12.4
Extreme 12.4
38.2
5 years 12.4
Extreme 12.4
126
10 years 12.4
Extreme 12.4
162
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.88% - - 2.94B
-1.87%+4.22%+44.36%+0.58% 82.65B
-0.57%+1.27%-16.61%-35.57% 60.24B
-2.23%+5.48%+478.96%+33.09% 58.11B
-2.03%-2.62%-8.63%+27.87% 49.68B
-4.58%-2.73%+1.79%+159.87% 46.66B
-1.64%+1.07%+56.98%-17.07% 32.63B
-0.98%+1.91%+46.30%+100.30% 25.69B
-0.19%-4.74%-0.68%+194.68% 22.73B
-1.13%-2.45%+64.66%+108.24% 16.54B
Average -1.52%-0.24%+74.13%+63.55% 43.88B
Weighted average by Cap. -1.85%+0.74%+86.73%+42.82%

Financials

2026 *2027 *
Net sales 423M 364M 342M 313M 585M 39.91B 586M 4.04B 1.57B 20.48B 1.59B 1.55B 65.97B 552M 475M 447M 408M 764M 52.13B 766M 5.28B 2.05B 26.75B 2.07B 2.03B 86.16B
Net income -241M -207M -195M -178M -333M -22.72B -334M -2.3B -893M -11.66B -904M -884M -37.56B -211M -182M -171M -156M -292M -19.93B -293M -2.02B -784M -10.23B -793M -775M -32.94B
Net Debt -458M -394M -371M -338M -633M -43.21B -635M -4.38B -1.7B -22.17B -1.72B -1.68B -71.42B -381M -328M -308M -282M -527M -35.96B -528M -3.64B -1.41B -18.45B -1.43B -1.4B -59.43B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change
04/09/26 €22.40 0.00%
03/09/26 €22.40 +0.90%
02/09/26 €22.20 +4.72%
01/09/26 €21.20 -1.85%
31/08/26 €21.60 -4.42%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
26.23USD
Average target price
33.14USD
Spread / Average Target
+26.34%

Quarterly revenue - Rate of surprise